B-cell activating factor in the pathophysiology of multiple myeloma: A target for therapy?

Blood Cancer Journal

Volumn 5, Issue 2, 2015, Pages

  Hengeveld, P J ^a   Kersten, M J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATACICEPT; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; B CELL MATURATION ANTIGEN; GSK 2857916; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TABALUMAB; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; UNCLASSIFIED DRUG; TNFRSF13B PROTEIN, HUMAN; TNFSF13B PROTEIN, HUMAN;

B LYMPHOCYTE; BONE MARROW; CANCER SURVIVAL; CELL COMPONENT; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONJUGATE; HUMAN; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOLOGICAL PROCESS; PLASMA CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SURVIVAL FACTOR; TUMOR MICROENVIRONMENT; BIOSYNTHESIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

B-CELL ACTIVATING FACTOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; TUMOR MICROENVIRONMENT;

EID: 84927940092     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2015.3     Document Type: Review

References (80)

1. Ferlay J, Shin R, Bray F, Forman F, Mathers C, Parkin D. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Parkin D, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Kumar S, Witzig T, Timm M, Haug J, Wellink L, Fonseca R et al. Expression of VEGF and its receptors by myeloma cells. Leukemia 2003; 17: 2025-2031.
4. Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or suppressor? Nature 2003; 3: 756-767.
5. Giuliani N, Storti P, Bolzoni M, Palma BD, Bonomini S. Angiogenesis and multiple myeloma. Cancer Microenviron 2011; 4: 325-337.
6. Roccaro M, Sacco A, Maiso P, Kareem A, Azab A, Tai Y et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest 2013; 123: 1542-1555.
7. Ribatti D, Moschetta M, Vacca A. Microenvironment and multiple myeloma spread. Thromb Res 2014; 133: S102-S106.
8. Tanaka Y, Abe M, Hiasha M. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res 2007; 13: 816-823.
9. Karadag A, Oyajobi B, Apperley J, Russell R, Croucher P. Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts. Br J Haematol 2000; 108: 383-390.
10. Moreaux J, Legouffe E, Jourdan E, Quittet P, Rème T, Lugagne C et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2003; 103: 3148-3157.
11. Navarra S, Guzmán R, Gallacher A, Hall S, Levy R, Jimenez R et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-731.
12. Moore P, Belvedere O, Orr A, Pieri K, LaFleur D, Feng P et al. BlyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260-263.
13. Mukhopadhyay A, Ni J, Zhai Y, Yu G, Aggarwal B. Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-κB, and c-Jun NH2-terminal kinase. J Biol Chem 1999; 274: 15978-15981.
14. Shu H, Hu W, Johnson H. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol 1999; 65: 680-683.
15. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer J, Holler N et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189: 1747-1756.
16. Roschke V, Sosnovsteva S, Ward C, Hong J, Smith R, Albert V et al. BlyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002; 169: 4314-4321.
17. Liu Y, Xu L, Opalka N, Kappler J, Shu H, Zhang G. Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands. Cell 2002; 108: 383-394.
18. Bossen C, Schneider P. BAFF, APRIL and their receptors: Structure, function and signaling. Sem Immunol 2006; 18: 263-275.
19. Gavin A, Duong B, Skog P, Aït-Azzouzene D, Greaves D, Scott M et al. ΔBAFF, a splice isoform of BAFF, opposes full-length BAFF activity in vivo in transgenic mouse models. J Immunol 2005; 175: 319-328.
20. Day E, Cachero T, Qian F, Sun Y, Wen D, Pelletier M et al. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry-US 2005; 44: 1919-1931.
21. Bossen C, Cachero T, Tardivel A, Ingold K, Willen L, Dobles M et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B-cells and plasmablasts. Blood 2008; 111: 1004-1012.
22. Zhang L, Zheng S, Wu H, Wu Y, Liu S, Fan M et al. Identification of BLyS (B lymphocyte stimulator), a non-myelin-associated protein, as a functional ligand for Nogo-66 receptor. J Neurosci 2009; 29: 6348-6352.
23. Schiemann B, Gommerman J, Vora K, Cachero T, Shulga-Morskaya S, Dobles M et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001; 293: 2111-2114.
24. Tardivel A, Tinel A, Lens S, Steiner Q, Sauberli E, Wilson A et al. The anti-apoptotic factor Bcl-2 can functionally substitute for the B cell survival but not for the marginal zone B cell differentiation activity of BAFF. Eur J Immunol 2004; 34: 509-518.
25. Sasaki Y, Casola S, Kutok J, Rajewsky K, Schmidt-Supprian M. TNF family member B-cell activating factor (BAFF) receptor-dependent and-independent roles for BAFF in B-cell physiology. J Immunol 2004; 173: 2242-2252.
26. Gioia C, Silini A, Fiorini C, Soresina A, Meini A, Ferrari S et al. Mutational analysis of human BAFF receptor TNFRSF13C (BAFF-R) in patients with common variable immunodeficiency. J Clin Immunol 2005; 25: 496-502.
27. Mackay F, Woodcock S, Lawton P, Ambrose C, Baetscher M, Schneider P et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190: 1697-1710.
28. Xu S, Lam K. B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol Cell Biol 2001; 21: 4067-4074.
29. O'Connor B, Raman V, Erickson L, Cook W, Weaver L, Ahonen C et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004; 199: 91-97.
30. Seshasayee D, Valdez P, Yan M, Dixit V, Tumas D, Grewal I. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003; 18: 279-288.
31. Litinskiy M, Nardelli B, Hilbert D, He B, Schaffer A, Casali P et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nature Immunol 2002; 3: 822-829.
32. Castigli E, Wilson S, Garibyan L, Rachid R, Bonilla F, Schneider L et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nature Genet 2005; 37: 829-834.
33. Salzer U, Jennings S, Grimbacher B. To switch or not to switch-the opposing roles of TACI in terminal B cell differentiation. Eur J Immunol 2007; 37: 17-20.
34. Scapini P, Bazzoni F, Cassatella M. Regulation of B-cell-activating factor (BAFF)/B lymphocyte stimulator (BLyS) expression in human neutrophils. Immunol Lett 2008; 116: 1-6.
35. Boulé M, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin I. Toll-like receptor 9-dependent and-independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 2004; 199: 1631-1640.
36. Gorelik L, Gilbride K, Dobles M, Kalled S, Zandman D, Scott M. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med 2003; 198: 937-945.
37. Riccobene T, Miceli R, Lincoln C, Knight Y, Meadows J, Stabi M et al. Rapid and specific targeting of 125 I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice. J Nucl Med 2003; 44: 422-433.
38. Novak A, Darce J, Arendt B, Harder B, Henderson K, Kindsvogel W et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004; 103: 689-694.
39. Moreaux J, Cremer F, Reme T, Raab M, Mahtouk K, Kaukel P et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005; 106: 1021-1030.
40. Jiang P, Yueguo W, Huiming H, Hongxiang Y, Mei W, Ju S. B-Lymphocyte stimulator: a new biomarker for multiple myeloma. Eur J Haematol 2009; 82: 267-276.
41. Li W, Li J, Su C, Zou W, Luo S. New targets of PS-341: BAFF and APRIL. Med Oncol 2010; 27: 439-445.
42. Moreaux J, Sprynski A, Dillon S, Mahtouk K, Jourdan M, Ythier A et al. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop. Eur J Haematol 2009; 83: 119-129.
43. Tai Y, Li X, Breitkreutz I, Song W, Neri P, Catley L et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2006; 66: 6675-6682.
44. Neri P, Kumar S, Fulciniti M, Vallet S, Chhetri S, Mukherjee S et al. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res 2007; 13: 5903-5909.
45. Shen X, Zhu W, Zhang X, Xu G, Ju S. A role of both NF-kappaB pathways in expression and transcription regulation of BAFF-R gene in multiple myeloma cells. Mol Cell Biol 2011; 357: 21-30.
46. Xu G, Shen X, Pu J, Chu S, Wang X, Wu X et al. BLyS expression and JNK activation may form a feedback loop to promote survival and proliferation of multiple myeloma cells. Cytokine 2012; 60: 505-513.
47. Tarte K, Vos JD, Thykjaer T, Zhan F, Fiol G, Costes V et al. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood 2002; 100: 1113-1122.
48. Claudio J, Masih-Khan E, Tang H, Gonçalves J, Voralia M, Li Z et al. A molecular compendium of genes expressed in multiple myeloma. Blood 2002; 100: 2175-2186.
49. Bellucci R, Wu C, Chiaretti S, Weller E, Davies F, Alyea E et al. Complete response to donor lymphocyte infusion in multiple myeloma is associated withantibody responses to highly expressed antigens. Blood 2004; 103: 656-663.
50. Nakamura N, Hase H, Sakurai D, Yoshida S, Abe M, Tsukada N et al. Expression of BAFF-R (BR3) in normal and neoplastic lymphoid tissues characterized with a newly developed monoclonal antibody. Virchows Arch 2005; 447: 53-60.
51. Shen X, Zhang X, Xu G, Ju S. BAFF-R gene induced by IFN-γ in multiple myeloma cells is related to NF-κB signals. Cell Biochem Funct 2011; 29: 513-520.
52. Rodig S, Shahsafaei A, Li B, Mackay C, Dorfman D. BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. Hum Pathol 2005; 36: 1113-1119.
53. Wada K, Maeda K, Tajima K, Kato T, Kobata T, Yamakawa M. Expression of BAFF-R and TACI in reactive lymphoid tissues and B-cell lymphomas. Histopathology 2009; 54: 221-232.
54. Moreaux J, Veyrune J, Jd Vos, Klein B. APRIL is overexpressed in cancer: link with tumor progression. BMC Cancer 2009; 9: 1-9.
55. Sasaki Y, Calado D, Derudder E, Zhang B, Shimizu Y, Mackay F et al. NIK-expression amplifies, whereas ablation of its TRAF-3 binding domain replaces BAFF:BAFF-R mediated survival signals in B-cells. PNAS 2008; 105: 10883-10888.
56. Demchenko Y, Kuehl W. A critical role for the NFkB pathway in multiple myeloma. Oncotarget 2010; 1: 59-68.
57. Annunziata C, Davis E, Demchen Y, Bellamy W, Gabrea A, Zhan F et al. Frequent engagement of the classical and alternative NF-kB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12: 115-130.
58. Keats J, Fonseca R, Chesi M, Schop R, Baker A, Chng W et al. Promiscuous mutations activate the noncanonical NF-kB pathway in multiple myeloma. Cancer Cell 2007; 12: 131-144.
59. Sun J, Li Y, Yu M, Sun Y, Feng J, Shen B. Analysis of an anti-B lymphocyte stimulator monoclonal antibody B7 and its binding activity to myeloma and lymphoma cell lines. Hybridoma 2006; 25: 238-242.
60. Klein B, Zhang X, Jourdan M, Content J, Houssiau F, Aarden L et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989; 73: 517-526.
61. Ju S, Wang Y, Ni H, Wang X, Jiang P, Kong X et al. Correlation of expression levels of BLyS and its receptors with multiple myeloma. Clin Biochem 2009; 42: 387-399.
62. Fragioudaki M, Boula A, Tsikaris G, Psakaris F, Spanoukadis M, Papadakis I et al. B cell-activating factor: its clinical significance in multiple myeloma patients. Ann Hematol 2012; 91: 1413-1418.
63. Fragioudaki M, Tsikaris G, Pappa C, Aristeidou I, Tsioutis C, Alegakis A et al. Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma. Leuk Res 2012; 36: 1004-1008.
64. Bolkun L, Lemancewicz D, Jablonska E, Kulczynska A, Bolkun-Skornicka U, Kloczko J et al. BAFF and APRIL as TNF superfamily molecules and angio-genesis parallel progression of human multiple myeloma. Ann Hematol 2014; 93: 635-644.
65. Lemancewicz D, Bolkun L, Jablonska E, Kulczynska A, Bolkun-Skornicka U, Kloczko J et al. Evaluation of TNF superfamily molecules in multiple myeloma patients: Correlation with biological and clinical features. Leuk Res 2013; 37: 1089-1093.
66. Alexandrakis M, Roussou P, Pappa C, Messaritakis I, Xekalou A, Goulidaki N et al. Relationship between circulating BAFF serum levels with proliferating markers in patients with multiple myeloma. BioMed Res Int 2013; 2013: 1-6.
67. Wang P, Qian L, Yuan X, Hu C, Wang L, Huang Q et al. BlyS: a potential hallmark of multiple myeloma. Front Biosci 2013; 1: 324-331.
68. Breitkreutz I, Raab M, Vallet S, Hideshima T, Raje N, Mitsiades C et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008; 22: 1925-1932.
69. Abe M, Kido S, Hiasa M, Nakano A, Oda A, Amou H et al. BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma. Leukemia 2006; 20: 1313-1315.
70. Yaccoby S, Pennisi A, Li X, Dillon S, Zhan F, Barlogie B et al. Atacicept (TACI-Ig) inhibits growth of TACIhigh primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia 2008; 22: 406-413.
71. Rossi J, Moreaux J, Hose D, Requirand G, Rose M, Rouille V et al. Atacicept in relapsed/refractory multiple myeloma or active Waldenstrom's macro-globulinemia: a phase I study. Br J Cancer 2009; 101: 1051-1058.
72. Sanchez E, Li M, Kitto A, Li J, Wang C, Kirk D et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol 2012; 158: 727-738.
73. Ryan M, Hering M, Peckham D, McDonagh C, Brown L, Kim K et al. Antibody targeting of B-cell maturation antigen on malignant plasma cells. Mol Cancer Ther 2007; 6: 3009-3018.
74. Tai Y, Mayes P, Acharya C, Zhong M, Cea M, Cagnetta A et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 2014; 123: 3128-3138.
75. Carpenter R, Evbuomwam M, Pittaluga S, Rose J, Raffeld M, Yang S et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res 2013; 19: 2048-2060.
76. Petri M, Stohl W, Chatham W, McCune W, Chevrier M, Ryel J et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008; 58: 2453-2459.
77. Manetta J, Bina H, Ryan P, Fox N, Witcher D, Kikly K. generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor. J Inflamm Res 2014; 7: 121-131.
78. Raje N EF Jr, Richardson P, Schiller G, Hohl R, Cohen A et al. Phase 1 study of tabalumab, a human anti-BAFF antibody and bortezomib in patients with previously-treated multiple myeloma. ASH Annual Meeting and Exposition 2012. Abstract 447.
79. Castigli E, Scott S, Dedeoglu F, Bryce P, Jabara H, Bhan A et al. Impaired IgA class switching in APRIL-deficient mice. PNAS 2004; 101: 3903-3908.
80. Guadagnoli M, Kimberley F, Phan U, Cameron K, Vink P, Rodermond H et al. Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas. Blood 2011; 117: 6856-6865.